SUBSCRIBE
SUBSCRIBE
News   Drug Development

43% Relative Improvement Versus Control Group In Hard-To-Heal Venous Leg Ulcers Obtained With XCELLentis’ LyphoDerm(TM)

October 19, 2005 | 
1 min read

XCELLentis, a wholly owned subsidiary of Innogenetics, today announced the top line results of its open-label phase 2 clinical trial with LyphoDerm™ for the treatment of hard-to-heal venous leg ulcers.

Clinical research Phase II Europe
MORE ON THIS TOPIC
Set of crumpled lumps of different paper isolated on yellow background. Gritty dusty dotted effect, vector elements with jagged edges, old notebook sheets.
Cancer
Cancer Pipelines Shrink as Incyte, iTeos Cut Candidates Following Disappointing Data
December 13, 2024
 · 
2 min read
 · 
Tristan Manalac
Human liver organ and pills. World hepatitis day. National liver health awareness month. Liver transplantation, donation background. Save patient life in hospital with liver transplant
Postmarket research
Intercept’s Troubled Drug Ocaliva Linked to ‘Serious Liver Injury’: FDA
December 13, 2024
 · 
2 min read
 · 
Tristan Manalac
Novo Nordisk advertising flags and logo on facade
Regulatory
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
December 12, 2024
 · 
1 min read
 · 
Kate Goodwin
New York City, NY, USA - August 22, 2022: Pfizer world headquarters in New York City, USA. Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation.
Phase III
Pfizer’s Ibrance Improves Survival in New Breast Cancer Indication
December 12, 2024
 · 
1 min read
 · 
Annalee Armstrong